Quantitative viral load testing is the World Health Organization-recommended monitoring tool for diagnosing and confirming the failure of antiretroviral therapy. Furthermore, the WHO 2021 Infant Diagnostic guidelines provide recommendations for a Nucleic Acid Testing (NAT) based algorithm for qualitative diagnosis of HIV exposed infants (HEI).
We established framework agreements with diagnostic manufacturers in 2025 with the aim of bringing more transparency, integration and competition to the HIV viral load and EID market.
Procurement Strategy
Our procurement strategy focuses on both optimizing existing equipment and investments as well as supporting scale-up for integration and all-inclusive pricing. The long-term goal is to achieve simple, transparent and affordable pricing with optimal contracting and procurement modalities for analyzers and/or reagents for both new and existing investments. The core objectives of the strategy include equitable access to quality-assured products, accelerate introduction to innovative technologies, improve supply chain responsiveness, and encourage environmentally sustainable practices.
The Global Fund is committed to increasing access to diagnostic equipment. New suppliers interested in working with the Global Fund and other public sector buyers who would like access to our negotiated terms and pricing should contact Thomas Schuster at .
Additional resources are available below to download and access.